Breaking News
March 23, 2018 - Mom’s Pre-Pregnancy Waist Size Tied to Autism Risk
March 23, 2018 - AMD Treat-and-Extend Regimens OK: Ophthalmology Times
March 23, 2018 - Safe-sleep recommendations for infants have not reduced sudden deaths in newborns
March 23, 2018 - Survey finds inappropriate prescribing of antibiotics for hospitalized children
March 23, 2018 - Researchers propose alternative treatment to target lymphoma signaling at its root
March 22, 2018 - Compound found in beet extract could help slow progression of Alzheimer’s disease
March 22, 2018 - Lower temperatures can trigger the body’s ‘good’ fat formation at cellular level
March 22, 2018 - Sentinel lymph node biopsies could be safely avoided for some breast cancer patients
March 22, 2018 - Combined Preeclampsia Test Superior to U.K. Standards
March 22, 2018 - Exclusive breastfeeding in hospital associated with longer breastfeeding duration
March 22, 2018 - Researchers prove link between common childhood cancer and inflammation
March 22, 2018 - Targeting aberrantly active telomerase to treat therapy-resistant melanoma
March 22, 2018 - California’s tax on millionaires yields big benefits for people with mental illness, study finds
March 22, 2018 - Weight-loss surgery reduces risk for severe chronic kidney disease and kidney failure
March 22, 2018 - Study identifies two genes associated with extreme nausea and vomiting during pregnancy
March 22, 2018 - Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
March 22, 2018 - ‘Bionic Pancreas’ OK for Very Young T1D Patients
March 22, 2018 - Parkinson’s gene initiates disease outside of the brain
March 22, 2018 - NMSU researchers publish findings on effective measures to remedy stress among adolescents
March 22, 2018 - Immunotherapy combination increases overall survival in people with kidney cancer, study shows
March 22, 2018 - Gut microbiome may promote pancreatic cancer by inducing immune suppression
March 22, 2018 - New ocular inserts allow patient’s cornea to absorb more antibiotics
March 22, 2018 - FDA Alert: NeuroBlate Probe by Monteris Medical: Letter to Health Care Providers, Class I Recall
March 22, 2018 - Cessation of exercise can result in increased depressive symptoms
March 22, 2018 - Morning Break: Booze Study Brouhaha; Stem Cells for MS; Big Debt Problem
March 22, 2018 - New wearable tech from Western may hold big benefits for people with Parkinson’s
March 22, 2018 - Immune cells can repopulate in the retina after elimination, mice study shows
March 22, 2018 - States extend Medicaid for birth control, cutting costs — and future enrollment
March 22, 2018 - Research provides better understanding of how cancerous cells behave in low oxygen
March 22, 2018 - Menopausal hormone therapy taken soon after menopause may benefit the brain
March 22, 2018 - Booze Boosts Your Heart Rate
March 22, 2018 - Skeptical Cardiologist: Classifying Heart Failure
March 22, 2018 - Instead of nagging your spouse to lose weight, try going on a diet yourself
March 22, 2018 - Neem Biotech to share findings on cystic fibrosis biofilm disruption at ECFS Basic Science Conference
March 22, 2018 - Study uncovers new genetic cause of posterior polymorphous corneal dystrophy
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
March 22, 2018 - GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence
March 22, 2018 - Higher Risk of Brain Deficits in Older Alcoholics
March 22, 2018 - Top US health official resigns in conflict of interest
March 22, 2018 - Study shows benefits of hair loss drug in improving cognitive function and vascular health
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Neuroscientists move closer to developing tools for deciphering brain function
March 22, 2018 - New test methods with less fear
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds

Verseon presents second anticoagulation candidate for clinical trials at AHA 2017

image_pdfDownload PDFimage_print

The preclinical data, presented by Verseon’s Director of Discovery Biology Dr. Anirban Datta, shows that VE-2851 potently inhibits thrombin and is highly selective against a panel of related serine proteases. It has pharmacokinetics suitable for oral administration and was well tolerated in a 14-day dose-range finding study. In preclinical tests, the candidate also displays efficacy comparable to marketed anticoagulants, but with a significantly lower bleeding risk.  

Similar to Verseon’s first development candidate VE-1902, which is scheduled to enter phase I trials in early 2018, VE-2851 likewise does not disrupt platelet function, a critical component in wound healing, healthy tissue growth, and hemostasis (stopping of bleeding). This feature distinguishes Verseon’s class of anticoagulants from current NOACs and provides a biological rationale for the low bleeding risk.  

“The pharmacological profile of our anticoagulants puts us in the unique position to address the unmet need for long-term combination therapy with anti-platelets,” commented Verseon’s CEO Adityo Prakash. “This has the potential to have a major impact on the anticoagulation market.”

“We are excited to have two drug candidates heading to the clinic in 2018,” said Dr. Datta. “Both development candidates act as potent anticoagulants without disrupting platelet function. This may significantly reduce the risk of major adverse cardiovascular events and bleeding when used in conjunction with antiplatelet drugs.” 

Today’s anticoagulant market is dominated by the NOACs, oral anticoagulants with less need for constant monitoring and reduced drug and food interactions compared to their predecessors. However, the bleeding risk associated with the NOACs remains high, which is particularly problematic when they are co-dosed with antiplatelet drugs. Such life-long combination therapy is desired for the many patients suffering from both atrial fibrillation and coronary artery disease, but current treatment guidelines limit it to at most one year due to safety concerns. 

Dr. Datta’s presentation will be featured in Thrombosis.TV, a leading destination for venous and arterial thrombosis education, news, and expert opinion.  

Verseon uses a computer-driven drug discovery platform embedded in a comprehensive chemistry and biology workflow to design new drug candidates for a wide range of diseases. In addition to the anticoagulation program, the company currently has drug programs in diabetic macular edema, hereditary angioedema, and oncology. 

About Verseon’s anticoagulation program

Verseon’s potent, highly selective oral direct thrombin inhibitors have shown excellent efficacy in multiple preclinical studies, but do not disrupt platelet function. This unique feature could explain the low bleeding risk of these precision anticoagulants and makes them excellent candidates for use in long-term combination anticoagulant-antiplatelet therapy. Two development candidates are expected to enter clinical trials in 2018, one of which has also demonstrated very low renal clearance, a highly desirable property for patients with impaired kidney function. 

Tagged with:

About author

Related Articles